VIROPRO (VPRO.PK) today announced the appointment of Ms. Michelle Peake to the position of CEO of its wholly-owned subsidiary Alpha Biologics Sdn. Bhd. facility based in Penang, Malaysia. In her new role, Ms. Peake, who was formerly COO of Alpha Biologics, will additionally head business development activities for Viropro and Alpha in the Asian markets, a key part of the Company’s near-term growth strategy.

Ms. Peake, who will be based in Penang, will provide Viropro with her 16 years of experience in the research and development and GMP manufacturing of biologics and biopharmaceutical markets with such companies as Cambridge Cognition and Xenova (UK), and Agenix Ltd. (Australia).

According to Dr. Rajiv Datar, President and CEO of Viropro, “Recognizing the potentially great client demand for our GMP-based mammalian cell clinical and production services in Penang, we are delighted to have Michelle’s world-class leadership in biologics and biopharmaceuticals available to drive our growth plan both in Malaysia and throughout the Asian markets.”

Ms. Peake has just recently been appointed to the Industry Advisory Panel of the Science University for Malaysia, and will be the moderator for the biotech financing session at BioMalaysia 2011. She has also been asked to be a session chair at World Congress of Industrial Biotechnology, Xi’an, and has been invited to speak at the International Congress of Antibodies-2012, Beijing.

Company also announces it has filed its September 2010, 10Q and has initiated the YE audit process. As soon as the audited financials are filed, the Company will call for a stockholders meeting. As previously mentioned, the Company is seeking to return to full disclosure status on an expedited basis.

An updated factsheet is available for review and download on the Company’s website at www.viropro.com.

About Viropro, Inc.:

Viropro, Inc. conducts operations through its subsidiaries Viropro International Inc., Biologics Process Development, Inc., Alpha Biologics Ltd. and Alpha Biologics Sdn. Bhd. Viropro’s principal objective is to provide high-yield development and GMP manufacturing services to biopharmaceutical companies in global markets with unmet medical and/or market needs. The Company specializes in the transfer of its core and proprietary technologies for industrial production of biopharmaceutical therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. (www.viropro.com)

Viropro Inc. Safe Harbor Statement

Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements." Forward-looking statements in this release may be identified through the use of such words as "expects," "anticipates," "estimates," "believes," or statements indicating certain actions "may," "could," or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.

Viropro (CE) (USOTC:VPRO)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Viropro (CE).
Viropro (CE) (USOTC:VPRO)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Viropro (CE).